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ABSTRACT
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively 
induce apoptosis in cancer cells without causing damage to normal cells. However, 
some tumors are resistant to TRAIL monotherapy and clinical studies assessing 
targeted agents towards the TRAIL receptor have failed to show robust therapeutic 
activity. Evidence has shown that standard anti-mitotic drugs can induce synergistic 
apoptosis upon combination with TRAIL via cell cycle arrest. Polo like kinase-1 (PLK1) 
plays a critical role in different stages of cell cycle progression and mitosis. A number 
of investigations have demonstrated that PLK1 inhibition causes cell cycle arrest and 
mitotic catastrophe in non-small cell lung cancer (NSCLC), and we thus postulated 
that PLK1 inhibition could enhance TRAIL-induced apoptosis. We demonstrate that 
the combination of a TRAIL receptor agonist and a PLK1 inhibitor synergistically 
reduces cell viability, and strongly increases apoptosis in NSCLC cellular models. 
Consistent with our in vitro observations, this drug combination also significantly 
reduces tumor growth in vivo. Our data additionally reveal that G2/M cell cycle arrest 
and downregulation of Mcl-1 and signal transducer and activator of transcription 
3 (STAT3) activity following PLK1 inhibition may contribute to the sensitization 
of TRAIL-induced apoptosis in NSCLC. Together, these data support the further 
exploration of combined TRAIL and PLK1 inhibition in the treatment of NSCLC. 
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INTRODUCTION
Lung cancer is the leading cause of cancer-related 
death worldwide, with 80% of lung cancers classified as 
non-small cell lung cancer (NSCLC). The identification of 
somatic mutations in NSCLC has led to the development 
of targeted therapies. Despite impressive initial results, 
these treatments are not yet curative, due to the emergence 
of drug-resistant clones that confer resistance to these 
targeted agents. 
Tumor necrosis factor (TNF) is an apoptotic ligand 
that was primarily identified as a natural anti-cancer 
agent, due to its ability to induce apoptosis in cancer cells 
[1–3]. However, due to its lack of specificity, TNF has 
demonstrated an unfavorable toxicity profile in patients 
[4]. Accordingly, the development of agents that more 
directly target the apoptotic machinery and could lead 
to better therapeutic efficacy and less toxic side effects 
has generated a lot of interest. TNF-related apoptosis-
inducing ligand (TRAIL) also known as Apo-2 ligand, 
is a member of the TNF cytokine family. In contrast to 
TNF, pre-clinical investigations have shown that TRAIL 
can selectively induce apoptosis in cancer cells without 
causing damage to normal cells [5–10]. Moreover, TRAIL 
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plays an important role in innate and adaptive immunity 
and its activity is considered as a natural path to eliminate 
cancer cells [11]. Therefore, inducing/activating the 
TRAIL apoptotic pathway is a proposed strategy that has 
received considerable attention as a potential anti-cancer 
therapy [12, 13]. 
Although TRAIL can induce apoptosis in cancer cell 
lines, clinical trials with several TRAIL receptor-agonists, 
including recombinant human TRAIL (rhTRAIL), and 
an agonist monoclonal antibody specific for TRAIL 
receptors, have failed to show robust therapeutic 
activity in patients. It has also been shown that most 
primary cancers are intrinsically TRAIL resistant 
[14, 15]. In addition, phase II clinical studies have also 
been disappointing, demonstrating resistance to TRAIL 
receptor targeted agents in human cancers including 
NSCLC [16]. A number of studies have reported that 
targeting TRAIL receptor combined with standard 
systemic therapy such as cisplatin, camptothecin and 
paclitaxel, can considerably increase anti-tumor activity 
in experimental NSCLC models [14]. In addition, anti-
mitotic drugs such as doxorubicin or methotrexate induce 
synergistic apoptosis upon combination with TRAIL via 
cell cycle arrest [17]. 
Polo like kinase-1 (PLK1) has received attention 
as a candidate anti-cancer target as it plays a critical role 
in different stages of cell cycle progression and mitosis 
[18] including mitotic entry, G2/M checkpoint, spindle 
assembly maturation, chromosome segregation, and 
mitotic exit [19]. PLK1 is overexpressed in several tumor 
types [20–23] including NSCLC [24, 25]. In contrast, it 
is almost undetectable in most normal adult tissue [26]. 
Depleting PLK1 expression by RNA interference has 
been shown to specifically reduce cellular growth, induce 
mitotic arrest and strongly induce apoptosis in cancer cells 
including NSCLC cells, in particular when Ras mutated 
[25, 27–29]. PLK1 inhibition, furthermore, causes cell 
cycle arrest and mitotic catastrophe in NSCLC [30, 31]. 
We thus hypothesized that the combined targeting 
of two essential pathways for the malignant phenotype, 
namely the cell cycle progression pathway by PLK1 
inhibition and TRAIL apoptotic pathway, might have 
synergistic therapeutic efficacy. Although interesting 
clinical results suggest a possible role for TRAIL and 
PLK1 inhibition as monotherapy in cancer therapy, 
combined use of TRAIL receptor agonists and PLK1 
inhibitors has not yet been investigated. 
RESULTS
Effect of rhTRAIL and PLK1 inhibitor 
monotherapy in NSCLC cells 
We first examined the effects of rhTRAIL and 
the PLK1 inhibitor RO3280 as single agents in various 
NSCLC cell lines with different genetic backgrounds 
(H1975, PC9, HCC827, A549 and H358; see Table 1). The 
cells were treated with rhTRAIL in a concentration range 
of 0.02–200 ng/ml or with RO3280 (0.05–500 nM) for 
72 hours. The cell viability was measured (Figure 1A, 1B) 
and IC50 values were calculated from the dose curve using 
the Compusyn software (Supplementary Figure 1). As 
summarized in Table 1, PC9 cells were the most sensitive 
to rhTRAIL, while the other investigated cell lines 
exhibited intermediate-sensitivity or resistance to TRAIL 
with IC50 values above 200 ng/ml. The majority of the 
tested cell lines exhibited high sensitivity or intermediate-
sensitivity to RO3280 with varying IC50 values. However, 
the A549 cell line demonstrated resistance to RO3280 with 
an IC50 concentration above 500 nM. 
We further investigated three of these cell lines with 
representative genotypes: PC9 cells containing a single 
epidermal growth factor receptor (EGFR) mutation, 
H1975 cells containing a double EGFR mutation and A549 
cells harboring a K-Ras mutation. The apoptotic effect 
of rhTRAIL (2–200 ng/ml) and RO3280 (5–500 ng/ml) 
as single therapy was tested in the three NSCLC cell lines 
by examining poly (ADP-ribose) polymerase (PARP) 
cleavage. As shown in Figure 1C, rhTRAIL induced PARP 
cleavage in a dose dependent manner in TRAIL-sensitive 
PC9 cells and TRAIL-resistant H1975 cells. Single 
treatment with rhTRAIL resulted in low PARP activity 
in A549 cells, the most resistant of the tested cell lines. 
Treatment with RO3280 induced PARP cleavage in H1975 
and PC9 cells in a dose-dependent manner, but to a lesser 
extent in A549 cells (Figure 1D). 
RO3280 in combination with rhTRAIL 
synergistically reduces cell viability in NSCLC 
cells
Next, we examined whether we could increase the 
sensitivity of NSCLC cells to TRAIL-induced anti-tumor 
activity by testing a combination of rhTRAIL (20 ng/mL) 
and RO3280 (50 nM) in all five NSCLC cell lines. 
Statistical tests revealed in all cell lines a significant 
reduction of cell viability when cells were treated with 
the drug combination compared to single agent treatments 
(Figure 2A). 
We further investigated this drug combination in 
a time-course experiment. H1975, PC9 and A549 cells 
were simultaneously treated with RO3280 (50 nM) 
and rhTRAIL (20 ng/ml) for 24, 48, 72, and 96 hours 
respectively. The result demonstrates that the combined 
treatment reduces cell viability in a time-dependent 
manner in the three cell lines (Figure 2B). 
To ascertain the additive or synergistic nature of this 
drug combination, we calculated the combination index 
(CI) [32]. RO3280 (0.05–500 nM) was combined with 
rhTRAIL (0.02–200 ng/ml) at a constant ratio in H1975, 
PC9 and A549 cells. Cell viability was assessed after 
72 hours and the CI and fraction affected curve was 
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calculated using the Compusyn software. Synergistic 
effects were observed at IC50/ED50 in all cells, with 
strong synergism (CI = 0.1–0.3) in H1975 and very 
strong synergism (CI < 0.1) in A549 cells respectively 
(Figure 2C).
RO3280 enhances TRAIL-mediated apoptosis in 
NSCLC
Apoptotic activity was assessed by examining 
caspase-3 and PARP cleavage by western blot analysis. As 
shown in Figure 3A, caspase-3 activity was increased in 
H1975, PC9 and A549 cells treated with the combination 
of RO3280 (50 nM) and rhTRAIL (20 ng/ml) compared 
to control and single agent exposure. A similar result was 
also observed for PARP, where the combination treatment 
increased PARP cleavage in all tested cells (Figure 3A).
In addition, we confirmed apoptotic activity by 
examining the number of annexin-V positive cells via 
flow cytometric analysis (Figure 3B). Further statistical 
analysis from at least three independent experiments shows 
that cells treated with rhTRAIL alone demonstrated an 
apoptotic rate of approximately 7 to 17% while exposure to 
RO3280 induced an apoptotic rate of approximately 15 to 
22% in the investigated cell lines (Figure 3C). Significantly 
higher level of apoptotic activity of approximately 38 
to 58% was observed in all cells treated with the drug 
combination. 
PLK1 inhibition sensitizes cells to TRAIL-
mediated apoptosis by blocking the cell cycle
The effect of the drug combination on the cell cycle 
was assessed by flow cytometry in NSCLC cell lines. As 
Table 1: Effect of rhTRAIL and PLK1 inhibitor in different NSCLC cell lines
Cell lines Oncogene mutation status RO3280IC50 (nM)
rhTRAIL
IC50 (ng/mL)
PC9 EGFR mutation (delE746-A750) 50 30.74 
H358 KRAS mutation (G12C) 58 >200 
HCC827 EGFR mutation (delE746-A750) 69 >200 
H1975 EGFR double mutation (p. L858R/T790M) 224 >200 
A549 KRAS mutation (G12S) >500 >200 
Figure 1: Cytotoxicity of rhTRAIL or PLK1 inhibitor RO3280 monotherapy in NSCLC cells. H1975, PC9, HCC827, 
A549 and H358 cells were treated with increasing concentrations of rhTRAIL (0.02, 0.2, 2, 20, 200 ng/ml) (A) or PLK1 inhibitor RO3280 
(0.05, 0.5, 5, 50, 500 nM) (B). Cell viability was measured using MTS assay after 72 hours incubation (n = 4, mean ± SD) (A, B). H1975, 
PC9 and A549 cells treated with 5, 50, 500 nM RO3280 or 2, 20, 200 ng/ml rhTRAIL for 24 hours were prepared for western blot analysis 
to determine PARP cleavage levels (C, D).
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shown in Figure 4A–4C, rhTRAIL did not induce cell 
cycle arrest in H1975, PC9 and A549 cells. However, 
PLK1 inhibitor treatment resulted in an increase in the 
distribution of cells at the G2/M phase in all three cell 
lines, indicating cell cycle arrest at G2/M. PLK1-induced 
G2/M cell cycle arrest was not further affected when the 
cells were additionally treated with rhTRAIL in PC9 and 
A549 cells. Interestingly, in H1975 cells, the number 
of cells in the G2/M phase markedly increased in the 
combined treatment condition (Figure 4A).
To further investigate whether cell cycle inhibition 
is the mechanism involved in the synergism observed 
between PLK1 and rhTRAIL, caffeine was used to 
prevent G2/M cell cycle arrest. H1975, PC9, and A549 
cells were pre-treated with caffeine (300 µ/ml in H1975 
and A549 and 600 µ/ml in PC9) for 12–18 hrs followed 
by RO3280 and rhTRAIL treatment for 24 hrs. The 
results indicate that caffeine addition induced a G0/G1 
arrest (Supplementary Figure 2). Apoptotic activity was 
further examined by PARP cleavage analysis in caffeine-
treated and untreated cells. The result shows that PARP 
cleavage was markedly reduced in all caffeine-treated cells 
followed by RO3280 and rhTRAIL treatment (Figure 4D). 
Overall, these results suggest that cell cycle blocking in 
the G2/M phase potentially contributes to the sensitization 
of cells to TRAIL-induced apoptosis. 
Effect of RO3280 in combination with rhTRAIL 
on the TRAIL apoptotic pathway
To further decipher the molecular mechanism 
by which RO3280 and rhTRAIL induce apoptosis, we 
Figure 2: Synergistic effect of RO3280 and rhTRAIL combined treatment in NSCLC cells. Cells were cultured 
simultaneously with 50 nM RO3280 and 20 ng/ml rhTRAIL (A, B) and an increased concentration of RO3280 (nM) and rhTRAIL 
(ng/ml): 1) 0:0; 2) 0.05:0.02; 3) 0.5:0.2; 4) 5:2; 5) 50:20; 6) 500:200; 7) 5000:2000 (C). Cell viability was analyzed by MTS assays after 
72 hrs incubation (A) or at indicated time points (n = 4, mean ± SD) (B). The combination index/fraction affected curve was calculated 
with the Compusyn program (C). 
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examined the effects of the drugs on the expression of 
the TRAIL receptors TRAIL-R1 (Death receptor 4/DR4) 
and TRAIL-R2 (Death receptor/DR5), as well as on the 
cellular FLICE-like inhibitory protein (FLIP) protein 
that is known to control the classical death receptor-
mediated extrinsic apoptosis pathway. Our results indicate 
that RO3280 single treatment or RO3280/rhTRAIL 
combination treatment slightly increases DR5 protein 
levels in all the tested cell lines (Supplementary Figure 3). 
Differential effects were observed on DR4 and FLIP in the 
treated cells lines. DR4 levels were increased in H1975 
cells treated with RO3280 or RO3280/rhTRAIL but not 
in other tested cells lines. Similar treatment resulted in the 
reduction of FLIP expression levels in PC9 and A549, but 
not in H1975 cells. 
We then examined the effect of RO3280 and 
TRAIL on the expression of anti-apoptotic proteins such 
as x-linked inhibitor of apoptosis protein (XIAP) and the 
Bcl-2 protein family members Bcl-XL and Mcl-1. XIAP 
plays a crucial role in the TRAIL-induced apoptotic 
pathway as it counteracts apoptosis by directly inhibiting 
caspase-3 and caspase-9 [33]. Downregulation of Mcl-1 
was significantly observed in all three cell lines treated 
with RO3280 without an additional effect when combined 
with rhTRAIL (Figure 5A). Only a slight downregulation 
of the Bcl-XL and XIAP protein was observed in PC9 
cells treated with RO3280 alone or in combination with 
rhTRAIL (Figure 5A). Our result further demonstrates 
that RO3280 inhibits Mcl-1 protein expression in a dose-
dependent manner (Figure 5B), but not Bcl-XL and XIAP 
protein expression (data not shown).
We then sought to define whether Mcl-1 
downregulation by PLK1 inhibition also plays a role in 
the synergistic effect of combined RO3280 and rhTRAIL 
exposure. H1975, PC9 and A549 cells were transfected 
with an Mcl-1 encoding plasmid or a control plasmid. 
Figure 3: PLK1 inhibition by RO3280 increase TRAIL-induced apoptosis in NSCLC cells. H1975, PC9, and A549 cells 
were treated with a combination of RO3280 (50 nM) and TRAIL (20 ng/ml) for 24 h. PARP/caspase-3 activity was analyzed by western 
blot. For each cell lines, lysates were run in the same gels (A). Representative image of apoptotic activity measured by flow cytometry (Q1: 
necrotic cells; Q2: late apoptotic cells; Q3: early apoptotic cells; Q4: viable cells;) (B). Indicated percentage of apoptotic cells represent 
early as well as late apoptotic cells and are derived from 3 independent experiments (± SEM) (C).
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After 24 hrs of single or combined treatment, cells were 
harvested and assessed for apoptotic activity by measuring 
PARP cleavage. The results, as shown in Figure 5C, 
indicate that PARP cleavage was reduced in all Mcl-1 
overexpressing cells treated with combined treatment. 
Effect of RO3280 in combination with rhTRAIL 
on the survival pathway of NSCLC
As the combination of RO3280 and rhTRAIL can 
synergistically reduce cell viability and induce apoptosis in 
Figure 4: RO3280-induced G2/M cell cycle arrest sensitizes NSCLC cells to TRAIL-induced apoptosis. H1975, PC9 and 
A549 cells were treated with 50 nM RO3280 and 20 ng/ml rhTRAIL for 24 hrs. Cells were stained with 7-AAD and the cell cycle was 
analyzed by flow cytometry (A–C). Cells were treated with or without caffeine (300 µg/ml for H1975 and A549, 600 µg/ml for PC9 in 
serum free medium) for 12–18 hrs, followed by RO3280 and rhTRAIL treatment for 24 hrs. Cell lysates were analyzed by western blot with 
indicated antibodies. PARP cleavage normalized by β-Actin were quantified by Image studio (D).  
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NSCLC cells, we sought to further investigate additional 
relevant signaling pathways, such as the mitogen-activated 
protein kinases/extracellular signal-regulated kinases 
(MAPK/ERK), the Akt and, the janus kinase/signal 
transducers and activators of transcription (JAK/STAT) 
pathways, which play an essential role in the survival 
of NSCLC [34]. As shown in Figure 6A, treatment with 
RO3280 resulted in the downregulation of phosphorylated 
STAT3. Surprisingly, statistical analysis further shows that 
phosphorylated STAT3 downregulation in cells that were 
treated with the combination of RO3280 and rhTRAIL 
was significantly higher compared to single treatment. 
There was also a trend of Akt and ERK dephosphorylation 
in H1975 and PC9 treated with RO3280. However, the 
data were not statistically significant, except Akt activity 
downregulation in H1975 treated with RO3280 and 
rhTRAIL. 
To further confirm that the observed downregulation 
of STAT3 activity results from the synergistic effect of 
RO3280 and rhTRAIL, we transiently overexpressed 
STAT3 in H1975, PC9 and A549 cells followed by 
treatment with RO3280, rhTRAIL or their combination. 
As shown in Figure 6B, overexpression of STAT3 in 
RO3280/rhTRAIL treated cells reduced the amount of 
cleaved PARP, compared to cells transfected with control 
plasmid. In STAT3 overexpressing cells, Mcl-1 was not 
detected (data not shown). 
PLK1 inhibition by volasertib sensitizes cells to 
TRAIL-mediated apoptosis in vivo 
In the final part of the study we examined the effect 
of PLK1 inhibition on TRAIL-induced apoptosis in vivo. 
Volasertib, a PLK1 inhibitor that has been widely used in 
clinical trials was chosen to evaluate the PLK1 inhibition 
combined with rhTRAIL in a murine model of NSCLC. 
First, the combination of volasertib and rhTRAIL was 
verified in H1975, PC9 and A549 cells in vitro, and the 
results demonstrate the combination of volasertib and 
rhTRAIL reduces cell viability and increase apoptosis in 
all the tested cell lines (Supplementary Figure 4). 
We generated xenograft tumors by injecting 
subcutaneously PC9 cells into nude mice. When the 
tumors reached approximately 80–100 mm3, the mice were 
randomly assigned into four treatment groups (Vehicle 
control, volasertib, rhTRAIL and volasertib+ rhTRAIL 
groups). The mice were subsequently treated twice with 
the drugs (see Material and Methods and Figure 7A). The 
apoptotic activity was examined 24 hrs after the second 
treatment in two representative tumors from each group. 
We observed increased PARP cleavage in tumors that 
were treated with volasertib and rhTRAIL combined, but 
not in control or single treatments (Figure 7B). This result 
was further confirmed by the terminal deoxynucleotidyl 
transferase (TdT) dUTP nick-end labeling (TUNEL) assay, 
Figure 5: Mcl-1 downregulation by RO3280 increase TRAIL apoptotic activity in NSCLC cells. Cells were cultured with 
50 nM RO3280 and 20 ng/ml rhTRAIL (A) or 5, 50, 500 nM RO3280 for 24 h (B) The cell lysates were analyzed by western blot with 
indicated antibodies and immunoblot bands values are shown in histograms (n = 3, ± SEM) (A, B). Cells were transfected with an Mcl-1 
encoding plasmid or a control plasmid 24 hrs prior to treatment (C). The cells were further treated with RO3280 (50 nM) and rhTRAIL 
(20 ng/ml). After 24 hrs, cell lysates were analyzed by western blot. PARP cleavage normalized by β-Actin (C). 
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demonstrating a significant increase of TUNEL positive 
cells in the combination group (Figure 7C). From TUNEL 
assay tumor slides in Figure 7C, we also observed increased 
amounts of mitotic spindles in tumors that were treated with 
volasertib (4.8 ± 0.59%) or in combination with rhTRAIL 
(5.6 ± 0.64%) compared to rhTRAIL (1.5 ± 0.27%) and 
control (1.2 ± 0.33%) (Supplementary Figure 5). 
Tumor volume was monitored over time, and the 
relative tumor volume was calculated as the difference 
between the tumor volume after treatment compared 
to tumor volume at day 0 (start of the treatment day). 
Volasertib (Slope: 40 ± 6.13%) and rhTRAIL (Slope: 
34 ± 4.66%) single treatment did not significantly decrease 
relative tumor volume compared to vehicle control (Slope: 
43 ± 4.43%). However, combined treatment with volasertib 
and rhTRAIL (Slope: 12.8 ± 2.16%) significantly 
decreased the relative tumor volume compared to 
control and single treatments (Figure 7D and 7E). 
In addition, the weight of nude mice did not exhibit a 
significant change during experiments (Supplementary 
Figure 6), suggesting that single or combination treatment 
with volasertib and/or rhTRAIL, do not cause toxicity at 
used doses in mice.
DISCUSSION
Targeting cell cycle progression is considered as 
one of the possible mechanism to sensitize tumor cells to 
TRAIL-induced apoptosis [17]. However, this approach 
has not been tested in NSCLC cells. PLK1 is the best 
characterized member of the polo-like kinase family 
that is considered as an emerging anti-mitotic target for 
NSCLC [35]. While PLK1-directed monotherapy has 
demonstrated manageable side effects but limited clinical 
efficacy, combination therapy is considered as a potential 
strategy to improve drug efficacy. In the current work we 
show for the first time, that combining a PLK1 inhibitor 
with rhTRAIL significantly promotes apoptosis in vitro. 
We subsequently demonstrated that the combined drug 
treatment significantly increases apoptosis and suppresses 
tumor growth in an in vivo xenograft model. 
Inhibition of PLK1 kinase activity by PLK1 
inhibitors such as volasertib, BI 2536, and GSK461364 
has been shown to induce cell cycle arrest at the G2/M 
phase in glioblastoma cells, osteosarcoma and NSCLC 
cells [30, 31, 36–38]. In our study, we showed that the 
fraction of NSCLC cells in the G2/M phase increased 
upon inhibition of PLK1 indicating a cell cycle arrest 
in this phase. Additionally, using a xenograft model of 
NSCLC we demonstrated that PLK1 inhibition increases 
the occurrence of mitotic spindles, which further deciphers 
that PLK1 inhibition induces cell cycle arrest possibly at 
the mitotic level. Indeed, our results are in agreement with 
investigations by Zhang et al. which revealed that blocking 
PLK1 kinase activity induces G2/M arrest and mitotic 
phase arrest in bladder carcinoma cell lines [39]. We further 
Figure 6: The influence of RO3280/rhTRAIL combined treatment on the signaling pathway in NSCLC cells. H1975, 
PC9, and A549 cells were treated with a combination of RO3280 (50 nM) and rhTRAIL (20 ng/ml) for 24 hrs and cell lysates were analyzed 
by western blot with indicated antibodies (A). Quantification of immunoblot analysis blots are shown in histogram (n = 3, ± SEM) (A). 
Cells were transfected with STAT3 plasmid or a control plasmid 24 hrs prior to drugs treatment and were further treated with RO3280 
(50 nM) and rhTRAIL (20 ng/ml) (B). After 24 hrs, cell lysates were analyzed by western blot with indicated antibodies (B). PARP cleavage 
normalized by β-Actin were quantified by Image studio. Cell lysates for each cell line were run in the same gels (B). 
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demonstrated that inducing G0/G1 arrest with caffeine in 
NSCLC cells, markedly suppresses the synergistic effect of 
a PLK1 inhibitor combined with a TRAIL agonist. Taken 
together, our results provide support for the conceptual 
premise that G2/M cell cycle arrest, possibly at the mitotic 
phase, is beneficial for the sensitization to TRAIL-induced 
apoptosis in lung cancer cells. 
The balance between apoptosis and cell cycle 
regulators may influence the destiny of cell homeostasis, 
with improper regulation, both mechanisms could 
contribute to pathological conditions including cancer. It is 
likely that these two mechanisms are directly or indirectly 
linked, as several genes involved in cell cycle regulation 
such as p53, Myc and pRb are also involved in apoptosis 
Figure 7: PLK1 inhibition increase TRAIL-induced apoptosis on xenograft model. Nude mice carrying PC9 tumors on left 
and right flanks (10 tumors per group, 17 tumors for control group) receive vehicle (4% dimethyl sulfoxide (DMSO) in corn oil), volasertib 
(20 mg/kg) or rhTRAIL (10 mg/kg) on day 0 and 3 through intraperitoneal injection (A). On day 4, representative mice from each group 
were sacrificed and tumors were excised. Two representative tumors from each group were analyzed for apoptotic activity by western 
blot using indicated antibody (B) and TUNEL assay (C). Representative field (Scale bar: 100 µm) with insert magnification (Scale bar: 
20 µm) (Red arrows: TUNEL positive cells; Black arrows: mitotic spindle) (C). The percentage of TUNEL positive cells (% total cells) 
were calculated from 10 random fields (n = 10, mean ± SEM) (C). Also see Supplementary Figure 5 for mitotic spindle calculation. Relative 
tumor volume was measured (mean ± SEM) for 10 days. The relative tumor volume in the treatment groups (n = 8 tumors) versus control 
group (n = 15 tumors) was compared using linear regression, with best fit values (D). Visualization of excised tumors from all treatment 
groups (E). 
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[40, 41]. Cell cycle arrest mediated by p53 has been 
previously described as a mechanism by which cytotoxic 
drugs sensitize tumor cells to TRAIL-induced apoptosis 
[17]. Hence future studies may focus on p53 to reveal the 
full mechanisms of how cell cycle arrested by PLK1 could 
increases TRAIL-induced apoptosis. 
TRAIL triggers the apoptotic pathway by binding 
to its trans-membrane receptors DR4 and DR5, inducing 
apoptotic signals via DISC and caspase-8 activation 
(Type I), or via the mitochondrial pathway (Type II) if 
caspase-8 activation is not sufficient to induce apoptosis. 
We observed a slight increase in DR5 expression following 
PLK1 inhibition, however, it remains to be tested whether 
DR5 upregulation is involved in the sensitization of 
TRAIL-induced apoptosis. Another mechanism of PLK1-
TRAIL synergy may be the inhibition of anti-apoptotic 
molecules in the mitochondria. The mitochondrial pathway 
is controlled by the pro-apoptotic Bcl-2 family members 
Bax and Bak, but also by anti-apoptotic Bcl-2 family 
members such as Mcl-1 and Bcl-XL [14, 15]. In response 
to PLK1 inhibition, our result demonstrate downregulation 
of Mcl-1, thereby increasing the sensitivity of NSCLC 
cells to TRAIL-induced apoptosis. 
Another interesting finding is that phosphorylation 
of STAT3 was significantly inhibited when the NSCLC 
cells were treated with RO3280 in combination with 
rhTRAIL. To date, there are not many documented studies 
investigating the relationship between PLK1 with the 
STAT3 pathway. One study in esophageal cancer revealed 
that STAT3 and PLK1 control each other’s transcription in 
a positive feedback loop [42]. The study also demonstrated 
that RNA interference mediated PLK1 RNA inactivation 
led to a decrease in STAT3 transcriptional activity in 
esophageal cancer cells [42]. However, in the present study 
we found that the level of phosphorylated STAT3 was 
influenced by PLK1 inhibition while the total amount of 
STAT3 protein was unaffected. Our finding thus warrants 
further investigation on the mechanism by which PLK1 
mediates STAT3 activity. Bcl-XL and Mcl-1 transcription 
are reported to be induced by activated STAT3 according 
to Rahaman et al. [43]. In addition, several other studies 
have also reported that TRAIL-mediated apoptosis is 
strongly increased when the anti-apoptotic Bcl-2 family 
member Mcl-1 is downregulated via JAK2-STAT3 
inhibition [44–46]. PLK1/STAT3 inhibition can possibly 
activate the Type II mitochondrial pathway via Mcl-1 
downregulation. However, our findings are not in 
agreement with the literature as Mcl-1 upregulation was 
not observed in STAT3-overexpressed NSCLC cells. 
We found that a combination of PLK1 inhibitor and 
rhTRAIL significantly reduces tumor growth. However, it 
is important to bear in mind that the combined treatment 
in the murine xenograft NSCLC tumor model was given 
in a short period, and at the minimal dosage. The optimum 
dose for complete tumor regression must be further 
investigated.
In conclusion, the present study reveals that TRAIL 
holds great promise for the treatment of NSCLC when 
used as a combinatorial strategy. Our corroborative in vivo 
results further support this. More importantly, no fatalities 
or toxicity were observed in the murine xenograft model, 
indicating the safety of the two drugs combined. The 
strong synergy of PLK1 inhibition and TRAIL activation 
may also represent a new form of synthetic lethality in 
NSCLC cells. Thus, we provide a rationale for the further 
exploration of the therapeutic potential and safety of 
TRAIL and PLK1 combination therapy in the treatment 
of NSCLC. 
MATERIALS AND METHODS
Cell culture and reagents
The Human NSCLC cell lines NCI-H1975, HCC827 
and H358 were obtained from the American Type Culture 
Collection (ATCC), while PC9 and A549 were obtained 
from Sigma. These cell lines were chosen based on their 
expression of mutated genes which are clinically relevant 
and represent the common heterogeneity of the disease. 
Cells identity was confirmed by STR analysis. All cells 
were cultured at 37° C in a humidified 5% CO2 incubator. 
H1975, PC9, HCC827 and H358 cells were grown in 
RPMI-1640 medium (Invitrogen) supplemented with 
10% heat inactivated fetal bovine serum (FBS) (Perbio 
Science), 2 mM L-glutamine and 25 mM HEPES. A549 
cells were grown in DMEM supplemented with 10% heat 
inactivated FBS, 2 mM L-glutamine and 25 mM HEPES. 
Stock Solution (10 mM) of RO3280 (Selleckchem) were 
prepared in dimethyl sulfoxide (DMSO) and stored at 
−80° C, further diluted in fresh medium prior to each 
experiment with the final concentration of DMSO less 
than 0.1%. Recombinant human TRAIL/Apo2 ligand was 
purchased from Peprotech and diluted in phosphate buffer 
saline (PBS).
Cell viability assay 
Cell viability was evaluated by the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Cell 
Titer96 Aqueous One Solution Cell Proliferation Assay, 
Promega). Cells were seeded into each well of 96 well 
plates and allowed to attach for 24 hours prior to the 
addition of DMSO or drugs. After drug treatment, 20 µl 
MTS solution was added to each well followed by 2 hours 
incubation. Cell viability was determined by measuring 
the absorbance at 490 nm with a 96 well microplate reader 
(Scientific Multiskan MK3, Thermo). Four replicate 
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wells were utilized for each analysis and at least three 
independent experiments were conducted.
Annexin V staining 
Cells were collected, washed with ice cold PBS 
and re-suspended in binding buffer (BD Biosciences). 
For apoptosis analysis the cells and supernatant were 
collected and were stained with APC fluorochrome-
labeled 5 µl Annexin V (BD Biosciences) combined with 
5 µl 7-Amino-Actinomycin (7-AAD) (BD Biosciences) 
to detect dead and damaged cells. The stained cells were 
analyzed by BD FACS Canto flow cytometry and were 
calculated using FlowJo® software. 
Cell cycle analysis 
Treated cells were trypsinized, washed with PBS 
and fixed in cold 70% ethanol. The single-cell suspensions 
were stained with 7-Amino-Actinomycin (7-AAD) (BD 
Biosciences) for subsequent analysis of the cell cycle by 
flow cytometry. 
Western blot analysis 
Cultured cells were washed in ice-cold PBS and 
lysed in lysis solution containing Tris/HCL (pH 7.6) 
20 mM, NaCl 150 mM (pH 6.85), EDTA 1 mM (pH 8), 
TRITON X 1%, Na-pyrophosphate 2.5 mM, sodium 
orthovanadate (Na3VO4) 1 mM, leupeptin 1 µg/ml, 
protease inhibitor cocktails 1% and phosphatase inhibitor 
cocktails 1% (Sigma). Protein concentration of the lysate 
was measured by the Bradford protein assay (Bio-Rad). 
Samples containing equal amounts of total protein were 
subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The resolved proteins were 
transferred from the gel to PVDF membranes and probed 
with indicated antibodies: STAT3, Akt, pSTAT3 (Tyr705, 
3E2), ERK1/2, pERK (Tyr 185/187), caspase-3, PARP, DR5, 
DR4, XIAP, Bcl-XL and Mcl-1 from Cell signaling; pAkt 
(Ser473) from Invitrogen; FLIP from Abcam and β-Actin 
from Sigma. Detection of bound primary antibodies was 
performed with Horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Anti-mouse or anti-rabbit IgG 
HRP linked, GE Healthcare) and visualized with the 
chemiluminescence detection kit (Western bright™ 
ECL, Advansta) with LI-COR Biosciences Odyssey® Fc 
Imaging System and analyzed with Image Studio™. 
Plasmid transfection 
The pTOPOMCL1 Plasmid (pcDNA3.1/V5HisTOPO 
backbone with CMV promotor) was a gift from Ulrich 
Maurer (Addgene plasmid # 21605). Cells were cultured 
in 96 wells plate 24 hours prior transfection. The plasmid 
(500 ng) was transfected using Lipofectamine™ 2000 
(Invitrogen) in Opti-MEM (Gibco by life technologies), 
according to the manufacturer’s instructions. The 
transfected cells were cultured at 37° C for 24 hours and 
analyzed for analysis. 
Xenografts studies
All the procedures related to animal handling, 
care, and treatment were performed according to the 
guidelines approved by the University of Gent Animal 
Care and Use Ethical Committee. Athymic female nude 
mice (3–4 weeks) were purchase from Charles River 
Laboratories. PC9 Cells (2 × 106) in 50% Matrigel were 
injected subcutaneously into right and left flanks of mice. 
Tumor-bearing mice were randomly assigned into four 
treatment groups (5 mice per group, 10 mice for control) 
and treatment initiated when xenografts reached volumes 
about 80–100 mm3. Tumors were measured using Vernier 
caliper and the volume was calculated using the formula: 
Volume = Length × Width × Width/2, where the width 
represents the shorter perpendicular dimension of the 
tumor. Volasertib was administered intraperitoneally (i.p.) 
at a dose of 20 mg/kg in corn oil (4% DMSO), while 
rhTRAIL was administered intraperitoneally at a dose 
of 10 m/kg in saline solution. For dual treatment groups, 
tumor-bearing mice received volasertib followed by 
rhTRAIL and control groups were given both vehicles 
TUNEL staining
Tumors were excised and fixed in 10% formalin. 
Tumor sections were analyzed for TUNEL activity using 
the “In situ Cell Death Detection Kit, POD” (Roche) 
according to the manufacturer’s instructions with 
hematoxylin counterstain. The percentage of apoptotic cells 
was calculated as the ratio of TUNEL positive nuclei to the 
total amount of nuclei. The percentage of mitotic spindles 
was calculated as the ratio of mitotic spindles to the total 
amount of nuclei. 
Statistical analysis 
The results are representative of three independent 
experiments unless stated otherwise. Values were 
presented as the mean ± standard error of the mean (SEM). 
The unpaired two-tailed t-test was used to determine 
the significance of the differences between two groups. 
ANOVA followed by the Tukey test was done for studies 
with more than two groups. Relative tumor growth in 
the in vivo study was compared using linear regression, 
with best fit values. The difference between groups was 
considered statistically significant when P < 0.05 (*), 
P < 0.01 (**) and P < 0.001 (***).
Analysis of drug combination effects
Analysis of drug combination was assessed by 
Compusyn software (ComboSyn, Inc.) as described 
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[32]. The combination index (CI) was used to express 
synergism (CI < 1), additive effect (CI = 1) or antagonism 
(CI > 1) [47]. 
Abbreviations 
CI: Combination index; DISC: Death-inducing 
signaling complex; DR4/5: Death receptor 4/5; FLIP: 
cellular FLICE-like inhibitory protein; NSCLC: Non-small 
cell lung cancer; PARP: Poly (ADP-ribose) polymerase; 
PLK1: Polo like kinase 1; rhTRAIL: recombinant 
human TRAIL; STAT3: Signal transducer and activator 
transcription 3; TNF: Tumor necrosis factor; TRAIL: 
Tumor necrosis factor related apoptosis-inducing ligand; 
TRAIL-R1/2: TRAIL Receptor 1 or 2; XIAP: X-linked 
inhibitor of apoptosis protein.
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